Immunovia

Declaration of Voting Results & Voting Rights Announcements • Nov 28, 2025

CHANGE IN NUMBER OF SHARES AND VOTES IN IMMUNOVIA AB (PUBL)

During November 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of shares resolved by the board of directors on 27 August 2025 and approved by the extraordinary general meeting on 29 September 2025, as well as the directed issue of shares to underwriters in the rights issue resolved by the board of directors on 29 October 2025, based on the authorization granted by the extraordinary general meeting on 29 September 2025. As of 28 November 2025, the registered number of shares and votes in Immunovia amounts to 672,666,892.

For further information, please contact

Jeff Borcherding, CEO

jeff.borcherding@immunovia.com

This information is such information that Immunovia AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 28 November 2025 at 14:00 CET.

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.

This information is information that Immunovia is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-11-28 14:00 CET.